nVerses Capital LLC Acquires New Holdings in Quanterix Co. (NASDAQ:QTRX)

nVerses Capital LLC bought a new position in shares of Quanterix Co. (NASDAQ:QTRX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 4,600 shares of the company’s stock, valued at approximately $60,000.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Quanterix by 3.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,916 shares of the company’s stock worth $941,000 after acquiring an additional 1,186 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Quanterix by 11.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 14,261 shares of the company’s stock valued at $188,000 after purchasing an additional 1,417 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after buying an additional 3,279 shares during the period. State Board of Administration of Florida Retirement System boosted its position in Quanterix by 42.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 14,341 shares of the company’s stock worth $338,000 after acquiring an additional 4,250 shares during the last quarter. Finally, American Century Companies Inc. grew its position in Quanterix by 14.5% in the second quarter. American Century Companies Inc. now owns 56,145 shares of the company’s stock valued at $742,000 after purchasing an additional 7,118 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.

Insider Buying and Selling at Quanterix

In other Quanterix news, Director David R. Walt acquired 47,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average cost of $13.29 per share, for a total transaction of $624,630.00. Following the transaction, the director now directly owns 1,487,342 shares in the company, valued at $19,766,775.18. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 6.90% of the company’s stock.

Quanterix Price Performance

Shares of NASDAQ QTRX opened at $12.34 on Tuesday. The business has a fifty day moving average price of $12.65 and a two-hundred day moving average price of $14.47. The stock has a market capitalization of $472.25 million, a PE ratio of -12.85 and a beta of 1.36. Quanterix Co. has a fifty-two week low of $10.50 and a fifty-two week high of $29.70.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $34.38 million for the quarter, compared to the consensus estimate of $34.19 million. Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. During the same period in the prior year, the company earned ($0.16) EPS. On average, equities analysts expect that Quanterix Co. will post -0.88 EPS for the current year.

Analyst Ratings Changes

QTRX has been the subject of several recent research reports. TD Cowen reduced their price target on Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a research report on Friday, August 9th. Scotiabank reduced their price objective on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a report on Monday, August 12th. Finally, The Goldman Sachs Group decreased their price target on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday, July 9th.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.